Release Date: December 18, 2025
Expiration Date: January 23, 2026
Activity Overview
Recent advances in molecular testing and targeted therapies have rapidly transformed care for non–small cell lung cancer (NSCLC), making personalized management possible across all disease stages. However, significant challenges persist in the early detection of actionable mutations, comprehensive biomarker testing, and the integration of novel agents with unique efficacy and toxicity profiles into everyday practice.
This live webinar series brings together expert faculty for interactive, case-based discussions tailored to community oncology practice. Participants will gain practical insights on implementing biomarker-driven strategies, selecting optimal therapies, and managing adverse events, enhancing confidence in advancing NSCLC care for diverse patient populations.
This educational activity is an archive of the live presentation held on December 10, 2025.
Target Audience
This educational program is primarily directed toward community-based oncologists involved in the treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate key biomarkers and their role in guiding targeted therapy selection in non-small cell lung cancer (NSCLC)
- Implement molecular testing strategies to identify actionable mutations in clinical practice
- Apply clinical trial evidence supporting the efficacy and safety of targeted therapies in NSCLC to manage patients with NSCLC with actionable mutations optimally
- Identify optimal strategies to manage adverse events associated with novel targeted therapies in NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here